Stock Mailbag, Generex, Sequenom, MELA Sciences, Cardium Therapeutics, Biodel

Image via CrunchBase Another great article from The Street's Adam Feuerstein in his Biotech Stock Mailbag. Mostly on stocks NOT to invest in, or stocks to short, and biopharma stocks for Put Options. Adam's a downer to most parties but he speaks the truth. Whether you like it or not. Sometimes I haven't liked it but if you are looking for long term growth Biotech Stocks you might want to take some of his advice. Plus, you can enter his FDA Drug Approval Contest for October. See what people think about the FDA Drug Approvals Contest.

Biotech Stock Mailbag: Generex

Sequenom's Stock Falls, Clouded With Uncertainty

Sequenom Inc (SQNM) has been a disaster of a trade today. Down huge. Today alone lost 39%, trading down to 3.46. A year ago Sequenom was trading at 21.41. They were recovering slightly from their FDA false data reports for their clinical studies on pre-natal testing for Down's Syndrome, or Trisomy 21.

Sequenom Inc (SQNM.O) shares plunged Tuesday, a day after the company removed almost its entire top management following an independent probe that found the company failed to prevent mishandling of data related to its prenatal Down Syndrome test.